DJIA 17,678.70 6.10 0.03%
NASDAQ 4,771.76 13.88 0.29%
S&P 500 2,057.09 5.27 0.26%
market minute promo

CEL-SCI Corp (NYSEMKT: CVM)

0.67 0.02 (3.86%)

REAL-TIME: Last trade at


company name or ticker

Recent Quotes

CVM $0.67 3.86%
1D 1W 3M 6M 1Y 2Y 3Y
Today's Open $0.65
Previous Close $0.65
Daily Range $0.62 - $0.67
52-Week Range $0.54 - $1.90
Market Cap $61.2M
P/E Ratio -1.32
Dividend (Yield) $0.00 (0.0%)
Volume 583,751
Average Daily Volume 282,845
Current FY EPS -$0.36

Sector

Healthcare

Industry

Drugs

CEL-SCI Corp (CVM) Description

The Company engages in the research and development of drugs and vaccines. Its most advanced product, Multikine, manufactured using the Company's proprietary cell culture technologies, is being developed for the treatment of cancer. Website: http://www.cel-sci.com/

News & Commentary

One Biotech Stock to Avoid

Our investing community's latest pick to avoid: Vical.

CEL-SCI Receives Regulatory Clearance to Expand Its Phase III Head and Neck Cancer Trial into Romani

CEL-SCI Receives Regulatory Clearance to Expand Its Phase III Head and Neck Cancer Trial into Romania

CEL-SCI Quarterly Patient Enrollment In Its Head And Neck Cancer Phase III Trial Increases Eight Fol

CEL-SCI Quarterly Patient Enrollment In Its Head And Neck Cancer Phase III Trial Increases Eight Fold Over Same Prior Year Period

CEL-SCI Enrolls 22 Patients During October In Its Phase III Immunotherapy Head And Neck Cancer Trial

4 Stocks Under $10 Making Big Moves Higher

Wednesday Sector Leaders: Drugs, Biotechnology Stocks

Cel-Sci's Enrollment Math Doesn't Add up

CEL-SCI Receives Regulatory Clearance To Expand Phase III Head And Neck Cancer Trial Into Turkey

Morning Market Losers

Cel-Sci Sees Rapid Enrollment For Phase III Head And Neck Cancer Trial

Insider Buying Is On The Rise In These 4 Rallying Stocks

See More CVM News...

CVM's Top Competitors

CVM $0.67 (3.86%)
Current stock: CVM
AMGN $159.73 (-0.05%)
Current stock: AMGN
GILD $107.12 (1.50%)
Current stock: GILD
BIIB $362.44 (1.37%)
Current stock: BIIB